Our News

Amneal Portfolio Acquisition

Friday 1st September 2017:  Juno Pharmaceuticals today announced it has acquired the Amneal injectables, ophthalmic, and oncology portfolio. This business primarily has a focus on Australian hospital customers. “Juno is excited to add the Amneal Australia’s hospital injectable, ophthalmic, and oncology range to its growing portfolio. The Amneal range complements many of the current Juno … Continue reading Amneal Portfolio Acquisition

Read More..

Juno Pharmaceuticals appointed by Celgene Pty as Strategic Partner for its maturing brand Vidaza® (5-azacitidine) in Australia

MELBOURNE, AUSTRALIA–Celgene Pty Ltd and Juno Pharmaceuticals Pty Ltd today announced the signing of a definitive agreement in which Celgene has appointed Juno as its strategic partner for its maturing brand – Vidaza® in Australia. Under the terms of the agreement, Juno will assist with the commercial management of Vidaza® in Australia. “By combining forces … Continue reading Juno Pharmaceuticals appointed by Celgene Pty as Strategic Partner for its maturing brand Vidaza® (5-azacitidine) in Australia

Read More..

Juno Appointed Exclusive Distributor for Hexvix®

Juno Pharmaceuticals is excited to announced it has been appointed as the exclusive distributor in Australia and New Zealand for Hexvix® (hexaminolevulinate hydro-chloride), an innovative breakthrough technology to aid in the diagnosis and management of non-muscle-invasive bladder cancer. The registration process will begin immediately and it is hoped that this product will be registered in 2016 In Australia, each … Continue reading Juno Appointed Exclusive Distributor for Hexvix®

Read More..

Medical Device Approval

Juno Pharmaceuticals is pleased to announce the TGA granted approval for the following Medical Device Class 3 application in February 2015: iAluRil Procedure Pack. iAluRil prefill contains: 800 mg/50 ml sodium hyaluronate (1.6%) and 1 g /50 ml sodium chondroitin sulfate (2%). iAluRil is  indicated to re-establish the glycosaminoglycan layers (GAGs) of the urothelial vesical tissue in cases … Continue reading Medical Device Approval

Read More..